Author: Chris Elkins

The National Cancer Institute has opened a promising clinical trial aimed at increasing the effectiveness of immunotherapy treatment for patients with unresectable malignant mesothelioma. This latest study involves combining LMB-100, a manmade protein designed to kill cancer cells, with ipilimumab, an immunotherapy drug recently approved for use by the U.S. Food and Drug Administration. Ipilimumab […]

The post NCI Opens New Immunotherapy Clinical Trial for Mesothelioma appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

A novel phase II clinical trial for malignant mesothelioma is expected to open soon and involve a versatile, biological drug already showing promise in treating severe cases of COVID-19. Oncotelic Therapeutics Inc., an innovative, immunotherapy/oncology company in Agoura Hills, California, hopes to open the mesothelioma clinical trial by March at a dozen prominent U.S. treatment […]

The post Mesothelioma Clinical Trial to Involve Drug Studied for COVID-19 appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

When it comes to malignant pleural mesothelioma, not everyone is treated equally. A disparity in access to care makes the difference in mesothelioma treatment quite dramatic, according to the University of Miami’s Sylvester Comprehensive Cancer Center. “Patients without access to expert multidisciplinary care at high-volume, academic facilities are being inappropriately undertreated for their disease,” medical […]

The post Study Shows Access to Care Often Difficult for Mesothelioma Patients appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Memorial Sloan Kettering Cancer Center continues its drive toward a future that may involve innovative CAR T-cell therapy as part of standard-of-care treatment for malignant pleural mesothelioma. The latest step was a clinical trial exploring a first-in-human, intrapleural-administered CAR T-cell therapy used in combination with pembrolizumab, a well-known immunotherapy drug also known by the brand […]

The post CAR T-Cell Therapy Showing Promise with Pleural Mesothelioma appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Johnson & Johnson is considering the creation of a new subsidiary to absorb its widespread asbestos liabilities, according to reports in The Wall Street Journal and other news outlets. The J&J subsidiary would then declare Chapter 11 bankruptcy, potentially saving the multinational corporation billions of dollars. Reuters News Service also reported the subsidiary possibility, citing […]

The post Johnson & Johnson Weighs Options for Talc Liabilities appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.